Skip to main content


RECOVER‐VITAL: A Platform Protocol for Evaluation of
Interventions for Viral Persistence, Viral Reactivation,
and Immune Dysregulation in Post‐Acute Sequelae of
SARS‐CoV‐2 Infection (PASC)

All genders
person-wave 18+
Recruiting now
More information  


Principal Investigator: Michael R. Jordan, MD, MPH

This is a prospective, multi-center, multi-arm, double-blind, randomized, controlled platform trial evaluating antiviral and other therapeutics for use in the treatment of Post-Acute Sequelae of COVID-19 (PASC). The hypothesis is that persistent viral infection and/or overactive/chronic immune response are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.

Study details

Inclusion Criteria
  • 1. ≥ 18 years of age at the time of enrollment
  • 2. Previous suspected, probable, or confirmed SARS‐CoV‐2 infection, as defined by the Pan
    American Health Organization
  • 3.At least two moderate symptoms from the same Symptom Cluster or one severe cluster-associated
    symptom identified via the Cluster Targeted COVID‐19 Symptom Questions (CTCSQ)with participant identifying new symptoms since COVID‐19 illness and having
    persisted for at least 12 weeks.
Exclusion Criteria
  • 1. Known active acute SARS‐CoV‐2 infection ≤ 4 weeks from consent
  • . Known severe anemia, defined as < 8 g/dL20
  • 3. Meeting symptom cluster exclusion for all eligible clusters
Study Requirements

Five Visits Six month length of participation Seven blood collections (including remote) No X-rays, CT scans, MRIs

Jump back to top